Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab + Rituximab/Venetoclax in Relapsed/Refractory CLL
NCT05069051Phase 2Active, not recruiting
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2022
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab in chronic lymphocytic leukemia (CLL), sponsored by University Hospital Tübingen. Started Jan 2022; status: active, not recruiting.
02
Drugs
belimumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT05069051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05069051.